<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutr Metab (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Nutr Metab (Lond)</journal-id><journal-title-group><journal-title>Nutrition &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="epub">1743-7075</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26788114</article-id><article-id pub-id-type="pmc">4717650</article-id><article-id pub-id-type="publisher-id">63</article-id><article-id pub-id-type="doi">10.1186/s12986-016-0063-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Replacing carbohydrate with protein and fat in prediabetes or type-2 diabetes: greater effect on metabolites in PBMC than plasma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Minjoo</given-names></name><address><email>minjookim@yonsei.ac.kr</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Gayoung</given-names></name><address><email>bcabo258@daum.net</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Miso</given-names></name><address><email>altth1004@hanmail.net</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Yoo</surname><given-names>Hye Jin</given-names></name><address><email>hyejin10432@hanmail.net</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Jeong</surname><given-names>Tae-Sook</given-names></name><address><email>tsjeong@kribb.re.kr</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Sang-Hyun</given-names></name><address><email>shleefm@gmail.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Jong Ho</given-names></name><address><phone>+82-2-2123-3122</phone><email>jhleeb@yonsei.ac.kr</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Research Center for Silver Science, Institute of Symbiotic Life-TECH, Yonsei University, Seoul, 03722 Republic of Korea </aff><aff id="Aff2"><label/>National Leading Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Department of Food and Nutrition, College of Human Ecology, Yonsei University, Seoul, 03722 Republic of Korea </aff><aff id="Aff3"><label/>Department of Food and Nutrition, Brain Korea 21 PLUS Project, College of Human Ecology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722 Republic of Korea </aff><aff id="Aff4"><label/>National Research Laboratory of Lipid Metabolism and Atherosclerosis, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141 Republic of Korea </aff><aff id="Aff5"><label/>Department of Family Practice, National Health Insurance Corporation Ilsan Hospital, Goyang, 10444 Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>13</volume><elocation-id>3</elocation-id><history><date date-type="received"><day>2</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>12</day><month>1</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Kim et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Active metabolism of peripheral blood mononuclear cells (PBMC) could suggest their suitability for metabolomics studies. This study examined whether reductions in PBMCs and plasma lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>) activities induced by dietary intervention affected the overall metabolic profiles of PBMC and plasma.</p></sec><sec><title>Methods</title><p>Eighty nonobese subjects aged 40&#x02013;70 years (18.5&#x02009;&#x02264;&#x02009;BMI&#x02009;&#x0003c;&#x02009;30&#x000a0;kg/m<sup>2</sup>) with prediabetes or newly-diagnosed type-2 diabetes were assigned to consume either the usual refined-rice diet (control group, n&#x02009;=&#x02009;40) or to replace refined rice with whole grains and legumes as carbohydrates (whole-grain group, n&#x02009;=&#x02009;40) for three meals per day during the 12-week intervention. Fasting PBMC and plasma metabolomes were profiled using UPLC-LTQ-Orbitrap mass spectrometry.</p></sec><sec><title>Results</title><p>After 12&#x000a0;weeks, changes in fasting glucose, HbA<sub>1c</sub>, HOMA-IR, MDA, ox-LDL, LDL particle size, plasma Lp-PLA<sub>2</sub> activity, and PBMC enzyme activity in the whole-grain group were significantly different from those in the control group before and after adjusting for baseline levels. The PBMC levels of L-leucine, oleamide, lysoPC (16:0), and lysoPC (18:0) in the whole-grain group showed greater reductions compared with those of the control group. Changes in plasma metabolites were not significantly different between the two groups. Changes in PBMC Lp-PLA<sub>2</sub> activity positively correlated with changes in L-leucine, oleamide, lysoPC (16:0), lysoPC (18:0), glucose, and ox-LDL, and negatively correlated with changes in LDL particle size.</p></sec><sec><title>Conclusions</title><p>This study showed that dietary intervention in prediabetic or type-2 diabetic patients had a greater effect on PBMC Lp-PLA<sub>2</sub> activity and metabolites compared with those of plasma metabolites.</p></sec><sec><title>Trial registration</title><p><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02191644">NCT02191644</ext-link></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Metabolites</kwd><kwd>Peripheral blood mononuclear cells</kwd><kwd>Prediabetes</kwd><kwd>Whole-grains and legumes</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003725</institution-id><institution>National Research Foundation of Korea</institution></institution-wrap></funding-source><award-id>NRF-2012M3A9C4048762</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Jong Ho</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Diabetes is an epidemic metabolic disorder; about 2.7 million Korean people (8.03&#x000a0;%) aged 30&#x000a0;years or older had type-2 diabetes (T2D) and 25.0&#x000a0;% of adults had prediabetes in 2013 according to Korean Diabetes Fact Sheet 2015. Diabetes-related mortality was steadily decreased since 2003 and ranked as the fifth leading cause of natural death [<xref ref-type="bibr" rid="CR1">1</xref>]. Prediabetes can be indicated by either impaired fasting glucose (IFG) by the American Diabetes Association criteria [<xref ref-type="bibr" rid="CR2">2</xref>] or impaired glucose tolerance (IGT) by World Health Organization criteria [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>Lipoprotein-associated phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>) independently predicts T2D incidence and may be involved in its etiology [<xref ref-type="bibr" rid="CR4">4</xref>]. In recent study, an inverse association was observed between protein intake and circulating Lp-PLA<sub>2</sub> activity, suggesting that nutritional factors may influence Lp-PLA<sub>2</sub> activity [<xref ref-type="bibr" rid="CR5">5</xref>]. An intervention study that replaced refined rice with whole grains and legumes reduced blood glucose, insulin, Lp-PLA<sub>2</sub> activity, and cardiovascular risk factors in patients with prediabetes or T2D [<xref ref-type="bibr" rid="CR6">6</xref>]. The effects of this intervention diet on plasma and peripheral blood mononuclear cell (PBMC) metabolites have not been determined.</p><p>PBMCs include monocytes and lymphocytes which are blood cells having a round nucleus. These blood cells are a critical component in the immune system to fight infection and adapt to intruders. Monocytes have a key role in onset and development of inflammatory reactions by generating bioactive molecules such as Lp-PLA<sub>2</sub> in response to inflammatory stimuli [<xref ref-type="bibr" rid="CR7">7</xref>]. Lymphocytes are consist of three major types; T cells, B cells, and natural killer cells. T cells and B cells are the major cellular components of the adaptive immune response, whereas natural killer cells are a part of the innate immune system. The production and release of Lp-PLA<sub>2</sub> by lymphocytes may become increased under inflammatory conditions [<xref ref-type="bibr" rid="CR8">8</xref>]. Dietary intervention induces PBMC gene expression changes, including downregulating genes involved in inflammatory processes [<xref ref-type="bibr" rid="CR9">9</xref>]. Therefore, changes in PBMC metabolites and Lp-PLA<sub>2</sub> activity after dietary intervention could reflect dynamic responses, which are not detectable in plasma metabolomics analyses. The aim of this 12-week intervention study was to examine whether reductions in PBMC and plasma Lp-PLA<sub>2</sub> activities induced by dietary intervention (replacement of refined rice with whole grains and legumes, and higher intake of vegetables) affected the overall metabolic profiles of PBMC and plasma in nonobese patients that exhibited IFG, IGT, or newly-diagnosed T2D.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Subjects and study design</title><p>Nonobese subjects aged 40&#x02013;70 years (18.5&#x02009;&#x02264;&#x02009;BMI&#x02009;&#x0003c;&#x02009;30&#x000a0;kg/m<sup>2</sup>) were recruited from the Health Service Center (HSC) at the Ilsan Hospital, Goyang, Korea, during January&#x02013;June 2013. Based on the HSC data, subjects who had IFG (100&#x02009;&#x02264;&#x02009;fasting glucose &#x0003c;126&#x000a0;mg/dL) or newly-diagnosed T2D (fasting glucose &#x02265;126&#x000a0;mg/dL) were referred to the Department of Family Medicine or Internal Medicine. Exclusion criteria included: current and/or past history of cardiovascular disease; liver or kidney dysfunction; thyroid or pituitary disease. Subjects who were taking medications or supplements also were excluded. A total of 82 subjects were enrolled. The macronutrient composition of each subject&#x02019;s usual diet corresponded to a typical diet with cooked refined rice. The purpose of the study was carefully explained to all participants, and written consent was obtained prior to their participation. The Institutional Review Board of the NHIC-sponsored Ilsan Hospital and Yonsei University provided ethical approval of the study protocol, which was performed according to the Helsinki Declaration.</p><p>The present study was performed in two phases, including a 2-week run-in phase consisting of the usual diet with refined rice, and a 12-week intervention phase. During the run-in period, two subjects who did not maintain their energy intake dropped out. The remaining 80 subjects were randomly subdivided into the two study groups, and were assigned to consume either the usual refined-rice diet (control group, n&#x02009;=&#x02009;40) or to replace refined rice with whole grains and legumes as carbohydrates (whole-grain group, n&#x02009;=&#x02009;40) for three meals per day during the 12-week intervention.</p></sec><sec id="Sec4"><title>Assessment of dietary intake and physical activity level</title><p>All subjects were given written and verbal instructions by a registered dietitian on completion of a 3-day (2&#x000a0;week&#x000a0;days and 1 weekend day) dietary record every 2&#x000a0;weeks throughout the study. On the dietary record sheet, subjects were instructed to weigh and record the food amount before and after ingestion. All participants were advised to continue their usual refined-rice diet during a 2-week run-in period. Baseline measurements were performed at the start of the run-in phase. After a run-in period, subjects in the control group maintained the usual refined-rice diet, whereas subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30&#x02013;70&#x000a0;g/unit) per day for sufficient dietary fiber intake. The dietitian monitored subject compliance and body-weight changes during the whole study by performing biweekly visits or telephone interviews and all participants were encouraged to maintain their usual lifestyles. Dietary energy values and nutrient contents from 3-day food records were calculated using the CAN-pro 3.0 (Korean Nutrition Society, Seoul, Korea). Total energy expenditures (kcal/day) were calculated from activity patterns including basal metabolic rate, physical activity for 24&#x000a0;h [<xref ref-type="bibr" rid="CR10">10</xref>], and specific food dynamic action. Basal metabolic rate for each subject was calculated with the Harris&#x02013;Benedict equation [<xref ref-type="bibr" rid="CR11">11</xref>].</p></sec><sec id="Sec5"><title>Anthropometry and blood pressure analysis</title><p>Body weight and height of unclothed subjects without shoes were measured in the morning for calculating body mass index (BMI, kg/m<sup>2</sup>). Waist circumference was measured on standing subjects at the umbilical level after normal expiration. Blood pressure (BP) of seated subjects after a 20-min rest was measured in the left arm with an automatic BP monitor (FT-200S, Jawon Medical, Gyeongsan, Korea). After a 12-h fasting period, venous blood specimens were collected in EDTA-treated and plain tubes and centrifuged to yield plasma or serum, respectively, which were stored at &#x02212;70&#x000a0;&#x000b0;C until analysis.</p></sec><sec id="Sec6"><title>Clinical measurements</title><p>Fasting total cholesterol and triglyceride levels were analyzed using a Hitachi 7600 Autoanalyzer (Hitachi Ltd., Tokyo, Japan). ApoB-containing lipoproteins were precipitated with dextran-magnesium sulfate, and high density lipoprotein (HDL)-cholesterol concentrations in patient serum samples were measured enzymatically. For subjects with serum triglyceride levels &#x0003c;400&#x000a0;mg/dL, low density lipoprotein (LDL)-cholesterol concentrations were estimated indirectly using the Friedewald formula. For subjects with serum triglyceride levels &#x02265;400&#x000a0;mg/dL, LDL-cholesterol concentrations were measured directly. Free fatty acids (FFA) were analyzed using the acyl-CoA synthetase&#x02009;&#x02212;&#x02009;acyl-CoA oxidase enzymatic assay method and a Hitachi 7600 Autoanalyzer.</p><p>All subjects underwent an oral glucose-tolerance test at 0 and 12&#x000a0;weeks by ingesting a 75&#x000a0;g glucose solution after a 12-h overnight fast. Venous specimens were collected before glucose loading, at loading, and 30, 60, and 120-min after loading to determine serum glucose levels and responses. Fasting glucose levels were analyzed by the hexokinase method using a Hitachi 7600 Autoanalyzer. Insulin levels were measured using an immunoradiometric assay kit from DIAsource ImmunoAssays S.A. (Louvain, Belgium). Hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) was measured by immonoturbidimetric analysis. Insulin resistance (IR) was calculated by the homeostasis-model assessment (HOMA) [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Whole blood was mixed with the same volume of RPMI 1640 (Gibco, Life Technologies, Gland Island, NY) and gently laid on a histopaque-1077 (Sigma-Aldrich, St. Louis, MO). The sample was then centrifuged at 1800&#x000a0;rpm for 20-min at 10&#x000a0;&#x000b0;C. After the separation, a thin layer of PBMCs was isolated and washed twice with RPMI 1640. The pellet was resuspended in RPMI 1640 with streptomycin. Isolated PBMCs were cultured in RPMI 1640 supplemented with 10&#x000a0;% fetal bovine serum (FBS), seeded in 12-well plates (1x10<sup>6</sup> cells/mL; SPL, Gyeonggi-do, Korea), and incubated at 37&#x000a0;&#x000b0;C with 5&#x000a0;% CO<sub>2</sub> for 22.5&#x000a0;h. After a 22.5&#x000a0;h incubation, 10&#x000a0;% FBS was added and incubated for 24.5&#x000a0;h. At third day, PBMC supernatants were collected and stored at &#x02212;80&#x000a0;&#x000b0;C until Lp-PLA<sub>2</sub> activity levels were assayed. Lp-PLA<sub>2</sub> activity in plasma and PBMC supernatants was measured by using a modification of a previously described high-throughput radiometric activity assay [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>Serum high-sensitivity C-reactive protein (hs-CRP) was measured with an ADVIA 2400 Clinical Chemistry System (Siemens Ltd., Tarrytown, NY) using a commercially available, hs-CRP-Latex(II) <italic>X</italic>2 kit (Denka-Seiken Co., Ltd., Tokyo, Japan). Plasma malondialdehyde (MDA) was measured from thiobarbituric acid&#x02009;&#x02212;&#x02009;reactive substances (TBARS) using the TBARS Assay Kit (ZeptoMetrix Co., Buffalo, NY). LDL particles were isolated by sequential flotation ultracentrifugation, and particle size distribution (1.019&#x02013;1.063&#x000a0;g/mL) was examined using a pore-gradient lipoprotein system (CBS Scientific Company, San Diego, CA) on commercially available, non-denaturing gels containing a linear 2&#x02013;16&#x000a0;% acrylamide gradient (CBS Scientific Company). Latex-bead (30&#x000a0;nm) conjugated thyroglobulin (17&#x000a0;nm), ferritin (12.2&#x000a0;nm), and catalase (10.4&#x000a0;nm) standards were used to estimate the relative band migration rates. Gels were scanned using a GS-800 Calibrated Imaging Densitometer (Bio-Rad Laboratories, Hercules, CA). Plasma oxidized (ox)-LDL was measured using an enzyme immunoassay (Mercodia AB, Uppsala, Sweden), and the resulting color reaction was determined at 450&#x000a0;nm on a Wallac Victor<sup>2</sup> multilabel counter (Perkin-Elmer Life Sciences, Boston, MA).</p></sec><sec id="Sec7"><title>Global (nontargeted) metabolic profiling of PBMC and plasma</title><sec id="Sec8"><title>PBMC and plasma extract sample preparation</title><p>Before analysis, 800&#x000a0;&#x003bc;L of 80&#x000a0;% acetonitrile was added to 100&#x000a0;&#x003bc;L of PBMC and plasma, mixed by vortexing, and centrifuged at 10,000&#x000a0;rpm for 5-min at 4&#x000a0;&#x000b0;C. The supernatant was dried with N<sub>2</sub> (l), dissolved in 10&#x000a0;% methanol, mixed by vortexing, and centrifuged at 10,000&#x000a0;rpm for 5-min at 4&#x000a0;&#x000b0;C. The supernatant was transferred into a vial.</p></sec><sec id="Sec9"><title>Ultra performance liquid chromatography</title><p>PBMC and Plasma extract samples (4&#x000a0;&#x003bc;L) were injected into an Acquity UPLC-BEH-C18 column (2.1&#x02009;&#x000d7;&#x02009;50&#x000a0;mm, 1.7&#x000a0;&#x003bc;m; Waters, Milford, MA) that was coupled in-line with a UPLC-LTQ-Orbitrap XL (Thermo Fisher Scientific, Waltham, MA). The injected samples were equilibrated with water containing 0.1&#x000a0;% formic acid. Samples were eluted with an acetonitrile gradient containing 0.1&#x000a0;% formic acid at a flow rate of 0.35&#x000a0;mL/min for 20-min. Metabolites were separated by UPLC, analyzed, and assigned by LTQ-Orbitrap-XL. The mass spectrometer (MS) was operated in ESI-positive mode. The spray voltage was 5&#x000a0;kV. The flow-rate nitrogen sheath gas and the auxiliary gas were 50 and 5 (arbitrary units). The capillary voltage (V), tube-lens voltage (V), and capillary temperature (&#x000b0;C) were kept constant at 35&#x000a0;V, 80&#x000a0;V, and 370&#x000a0;&#x000b0;C. Orbitrap data were collected in the range of <italic>m</italic>/<italic>z</italic> 50&#x02013;1,000. MS/MS spectra of metabolites were obtained by a collision-energy ramp from 55&#x02013;65&#x000a0;eV, and conducted with Xcalibur 2.1 and MS Frontier software (Thermo Fisher Scientific).</p></sec><sec id="Sec10"><title>Data processing and identification of metabolites</title><p>All MS data including retention times, <italic>m</italic>/<italic>z</italic>, and ion intensities were extracted by SIEVE software (Thermo Fisher Scientific) incorporated into the instrument, and the resulting MS data were assembled into a matrix. SIEVE parameters were set as follows: <italic>m</italic>/<italic>z</italic> range 50&#x02013;1,000; <italic>m</italic>/<italic>z</italic> width 0.02; retention time width 2.5; and <italic>m</italic>/<italic>z</italic> tolerance 0.005. Metabolites were searched using the following databases: ChemSpider (<ext-link ext-link-type="uri" xlink:href="http://www.chemspider.com">www.chemspider.com</ext-link>), Human Metabolome (<ext-link ext-link-type="uri" xlink:href="http://www.hmdb.ca">www.hmdb.ca</ext-link>), Lipid MAPS (<ext-link ext-link-type="uri" xlink:href="http://www.lipidmaps.org">www.lipidmaps.org</ext-link>), KEGG (<ext-link ext-link-type="uri" xlink:href="http://www.genome.jp/kegg">www.genome.jp/kegg</ext-link>), and MassBank (<ext-link ext-link-type="uri" xlink:href="http://www.massbank.jp">www.massbank.jp</ext-link>). Selected metabolites were confirmed by retention times and mass spectra of standard samples.</p></sec></sec><sec id="Sec11"><title>Statistical analyses</title><p>Statistical analyses were performed using SPSS v. 21.0 (IBM SPSS Statistics 21, Chicago, IL). Skewed variables were logarithmically transformed for statistical analyses. A two-tailed <italic>P</italic>-value of &#x0003c;0.05 was considered statistically significant. Differences in biochemical variables between two groups at baseline and follow-up were tested using Student&#x02019;s independent <italic>t</italic>-test. General linear model tests were applied to compare parameter changes between the two groups by adjusting for baseline values. Paired <italic>t</italic>-tests were used to evaluate differences between baseline and follow-up levels in each group. Pearson&#x02019;s and partial correlation coefficients were used to examine the relationships between variables over time. False discovery rate&#x02009;&#x02212;&#x02009;corrected <italic>q</italic>-values were computed using the R package &#x02018;fdrtool&#x02019;. Heat map was created to visualize and evaluate correlations among metabolites and conventional risk factors in study populations.</p><p>Multivariate statistical analysis was performed using SIMCA-P+ software version 12.0 (Umetrics, Ume&#x000e5;, Sweden). Partial least-squares discriminant analysis (PLS-DA) was used as the classification method for modeling the discrimination between groups by visualizing the score scatter plot or <italic>S</italic>-plot using the first and second PLS components. The goodness-of-fit was quantified by <italic>R</italic><sup>2</sup><italic>Y</italic>, whereas the predictive ability was quantified by <italic>Q</italic><sup>2</sup><italic>Y</italic>. Generally, <italic>R</italic><sup>2</sup><italic>Y</italic> describes how well the data in the training set were mathematically reproduced and varied between 0 and 1 (a value of 1 indicated a model with a perfect fit). Models with <italic>Q</italic><sup>2</sup><italic>Y</italic> &#x02265;0.5 were considered to have good predictive capabilities.</p></sec></sec><sec id="Sec12"><title>Results</title><sec id="Sec13"><title>Clinical characteristics, lipid profiles, and nutrient intake</title><p>There were no significant differences between two groups in baseline characteristics including age, gender, smoking, and drinking (data not shown). At baseline, there were no significant differences between two groups in BMI, waist:hip ratio (WHR), systolic BP, diastolic BP, serum triglyceride, total cholesterol, LDL-cholesterol, HDL-cholesterol, FFA, and hs-CRP. BMI, WHR, BP, serum lipid profiles, hs-CRP, total energy expenditure, and total energy intake were similar before and after the study in both groups (data not shown).</p><p>Replacement with whole grains and legumes caused significant increase in percent energy intake of protein and fat, and significant decrease in percent energy intake of carbohydrate. The percent energy intake of protein, fat, and carbohydrate significantly differed between the two groups before adjusting for baseline values. The whole-grain group had significant increases in fiber intake and polyunsaturated-to-saturated fatty acids ratio compared with baseline values. After 12-week, the whole-grain group had lower percent energy of carbohydrate, higher percent calorie of protein and fat, and fiber intake than control group (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Biochemical characteristics and estimates of daily nutrient intake before and after 12-week dietary intervention</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Control group (<italic>n</italic>&#x02009;=&#x02009;40)</th><th colspan="2">Whole-grain group (<italic>n</italic>&#x02009;=&#x02009;40)</th><th rowspan="2">
<italic>P</italic>
<sup>a</sup>
</th><th rowspan="2">
<italic>P</italic>
<sup>b</sup>
</th><th rowspan="2">
<italic>P</italic>
<sup>c</sup>
</th><th rowspan="2">
<italic>P</italic>
<sup>d</sup>
</th></tr><tr><th>Baseline</th><th>Follow-up</th><th>Baseline</th><th>Follow-up</th></tr></thead><tbody><tr><td>Glucose (mg/dL)<sup><italic>&#x0222e;</italic></sup>
</td><td>119.8&#x02009;&#x000b1;&#x02009;5.40</td><td>126.6&#x02009;&#x000b1;&#x02009;6.02<sup><italic>***</italic></sup>
</td><td>119.4&#x02009;&#x000b1;&#x02009;5.31</td><td>110.0&#x02009;&#x000b1;&#x02009;4.58<sup><italic>***</italic></sup>
</td><td>0.958</td><td>0.005</td><td colspan="2"/></tr><tr><td>Change</td><td colspan="2">6.78&#x02009;&#x000b1;&#x02009;1.51</td><td colspan="2">&#x02212;9.45&#x02009;&#x000b1;&#x02009;1.43</td><td/><td/><td>&#x0003c;0.001</td><td>&#x0003c;0.001</td></tr><tr><td>Glucose AUC (mg/dL&#x02009;&#x000d7;&#x02009;h)<sup><italic>&#x0222e;</italic></sup>
</td><td>376.8&#x02009;&#x000b1;&#x02009;17.7</td><td>390.4&#x02009;&#x000b1;&#x02009;22.9</td><td>376.6&#x02009;&#x000b1;&#x02009;18.9</td><td>352.0&#x02009;&#x000b1;&#x02009;17.5<sup><italic>*</italic></sup>
</td><td>0.923</td><td>0.225</td><td colspan="2"/></tr><tr><td>Change</td><td colspan="2">13.6&#x02009;&#x000b1;&#x02009;9.52</td><td colspan="2">&#x02212;24.7&#x02009;&#x000b1;&#x02009;8.75</td><td/><td/><td>0.004</td><td>0.004</td></tr><tr><td>HbA<sub>1c</sub> (%)<sup><italic>&#x0222e;</italic></sup>
</td><td>6.46&#x02009;&#x000b1;&#x02009;0.19</td><td>6.60&#x02009;&#x000b1;&#x02009;0.19<sup><italic>*</italic></sup>
</td><td>6.41&#x02009;&#x000b1;&#x02009;0.18</td><td>6.18&#x02009;&#x000b1;&#x02009;0.15<sup><italic>*</italic></sup>
</td><td>0.821</td><td>0.061</td><td colspan="2"/></tr><tr><td>Change</td><td colspan="2">0.14&#x02009;&#x000b1;&#x02009;0.06</td><td colspan="2">&#x02212;0.23&#x02009;&#x000b1;&#x02009;0.12</td><td/><td/><td>0.007</td><td>0.003</td></tr><tr><td>HOMA-IR<sup><italic>&#x0222e;</italic></sup>
</td><td>2.24&#x02009;&#x000b1;&#x02009;0.15</td><td>2.34&#x02009;&#x000b1;&#x02009;0.17</td><td>2.18&#x02009;&#x000b1;&#x02009;0.12</td><td>1.79&#x02009;&#x000b1;&#x02009;0.12<sup><italic>***</italic></sup>
</td><td>0.791</td><td>0.006</td><td colspan="2"/></tr><tr><td>Change</td><td colspan="2">0.10&#x02009;&#x000b1;&#x02009;0.11</td><td colspan="2">&#x02212;0.39&#x02009;&#x000b1;&#x02009;0.10</td><td/><td/><td>0.002</td><td>0.001</td></tr><tr><td>Insulin (&#x003bc;IU/mL)<sup><italic>&#x0222e;</italic></sup>
</td><td>7.58&#x02009;&#x000b1;&#x02009;0.35</td><td>7.47&#x02009;&#x000b1;&#x02009;0.43</td><td>7.58&#x02009;&#x000b1;&#x02009;0.43</td><td>6.72&#x02009;&#x000b1;&#x02009;0.46<sup><italic>**</italic></sup>
</td><td>0.798</td><td>0.132</td><td colspan="2"/></tr><tr><td>Malondialdehyde (nmol/mL)<sup><italic>&#x0222e;</italic></sup>
</td><td>9.24&#x02009;&#x000b1;&#x02009;0.53</td><td>10.2&#x02009;&#x000b1;&#x02009;0.61<sup><italic>***</italic></sup>
</td><td>9.41&#x02009;&#x000b1;&#x02009;0.39</td><td>8.70&#x02009;&#x000b1;&#x02009;0.37<sup><italic>**</italic></sup>
</td><td>0.530</td><td>0.041</td><td colspan="2"/></tr><tr><td>Change</td><td colspan="2">0.98&#x02009;&#x000b1;&#x02009;0.24</td><td colspan="2">&#x02212;0.71&#x02009;&#x000b1;&#x02009;0.24</td><td/><td/><td>0.001</td><td>&#x0003c;0.001</td></tr><tr><td>Oxidized LDL (U/L)<sup><italic>&#x0222e;</italic></sup>
</td><td>49.1&#x02009;&#x000b1;&#x02009;2.14</td><td>50.7&#x02009;&#x000b1;&#x02009;2.26</td><td>48.2&#x02009;&#x000b1;&#x02009;2.01</td><td>43.8&#x02009;&#x000b1;&#x02009;2.00<sup><italic>***</italic></sup>
</td><td>0.846</td><td>0.036</td><td colspan="2"/></tr><tr><td>Change</td><td colspan="2">1.65&#x02009;&#x000b1;&#x02009;0.90</td><td colspan="2">&#x02212;4.41&#x02009;&#x000b1;&#x02009;0.82</td><td/><td/><td>0.001</td><td>&#x0003c;0.001</td></tr><tr><td>LDL particle size (nm)<sup><italic>&#x0222e;</italic></sup>
</td><td>24.1&#x02009;&#x000b1;&#x02009;0.12</td><td>24.1&#x02009;&#x000b1;&#x02009;0.13</td><td>24.4&#x02009;&#x000b1;&#x02009;0.15</td><td>24.6&#x02009;&#x000b1;&#x02009;0.17<sup><italic>***</italic></sup>
</td><td>0.214</td><td>0.015</td><td colspan="2"/></tr><tr><td>Change</td><td colspan="2">&#x02212;0.05&#x02009;&#x000b1;&#x02009;0.06</td><td colspan="2">0.24&#x02009;&#x000b1;&#x02009;0.05</td><td/><td/><td>0.001</td><td>0.001</td></tr><tr><td>Plasma Lp-PLA<sub>2</sub> activity (nmol/mL/min)<sup><italic>&#x0222e;</italic></sup>
</td><td>30.1&#x02009;&#x000b1;&#x02009;1.64</td><td>30.3&#x02009;&#x000b1;&#x02009;1.61</td><td>28.0&#x02009;&#x000b1;&#x02009;1.20</td><td>25.7&#x02009;&#x000b1;&#x02009;1.11</td><td>0.874</td><td>0.701</td><td colspan="2"/></tr><tr><td>Change</td><td colspan="2">0.24&#x02009;&#x000b1;&#x02009;0.41</td><td colspan="2">&#x02212;2.38&#x02009;&#x000b1;&#x02009;0.55</td><td/><td/><td>0.001</td><td>&#x0003c;0.001</td></tr><tr><td>Unstimulated PBMC<break/>Lp-PLA<sub>2</sub> activity (nmol/mL/min)<sup><italic>&#x0222e;</italic></sup>
</td><td>2.00&#x02009;&#x000b1;&#x02009;0.12</td><td>2.28&#x02009;&#x000b1;&#x02009;0.13<sup><italic>**</italic></sup>
</td><td>2.16&#x02009;&#x000b1;&#x02009;0.12</td><td>1.90&#x02009;&#x000b1;&#x02009;0.12<sup><italic>**</italic></sup>
</td><td>0.365</td><td>0.046</td><td colspan="2"/></tr><tr><td>Change</td><td colspan="2">0.28&#x02009;&#x000b1;&#x02009;0.08</td><td colspan="2">&#x02212;0.26&#x02009;&#x000b1;&#x02009;0.10</td><td/><td/><td>0.001</td><td>&#x0003c;0.001</td></tr><tr><td colspan="9">Estimate of daily nutrient intake</td></tr><tr><td>Energy intake (kcal/d)</td><td>2,143&#x02009;&#x000b1;&#x02009;40</td><td>2,170&#x02009;&#x000b1;&#x02009;38</td><td>2,166&#x02009;&#x000b1;&#x02009;36</td><td>2,185&#x02009;&#x000b1;&#x02009;38</td><td>0.665</td><td>0.786</td><td colspan="2"/></tr><tr><td>Carbohydrate (%)</td><td>61.9&#x02009;&#x000b1;&#x02009;0.16</td><td>61.9&#x02009;&#x000b1;&#x02009;0.17</td><td>61.9&#x02009;&#x000b1;&#x02009;0.17</td><td>54.6&#x02009;&#x000b1;&#x02009;0.11</td><td>0.833</td><td>&#x0003c;0.001</td><td colspan="2"/></tr><tr><td>Protein (%)</td><td>16.3&#x02009;&#x000b1;&#x02009;0.10</td><td>16.3&#x02009;&#x000b1;&#x02009;0.08</td><td>16.3&#x02009;&#x000b1;&#x02009;0.10</td><td>20.5&#x02009;&#x000b1;&#x02009;0.13</td><td>0.851</td><td>&#x0003c;0.001</td><td colspan="2"/></tr><tr><td>Fat (%)</td><td>22.1&#x02009;&#x000b1;&#x02009;0.16</td><td>22.2&#x02009;&#x000b1;&#x02009;0.15</td><td>22.1&#x02009;&#x000b1;&#x02009;0.16</td><td>24.9&#x02009;&#x000b1;&#x02009;0.15</td><td>0.731</td><td>&#x0003c;0.001</td><td colspan="2"/></tr><tr><td>Crude fiber (g)<sup><italic>&#x0222e;</italic></sup>
</td><td>25.2&#x02009;&#x000b1;&#x02009;1.20</td><td>22.8&#x02009;&#x000b1;&#x02009;1.19</td><td>24.5&#x02009;&#x000b1;&#x02009;1.21</td><td>28.4&#x02009;&#x000b1;&#x02009;1.18</td><td>0.713</td><td>0.001</td><td colspan="2"/></tr><tr><td>PUFA/SFA</td><td>2.10&#x02009;&#x000b1;&#x02009;0.18</td><td>2.10&#x02009;&#x000b1;&#x02009;0.16</td><td>2.29&#x02009;&#x000b1;&#x02009;0.16</td><td>2.98&#x02009;&#x000b1;&#x02009;0.17</td><td>0.418</td><td>&#x0003c;0.001</td><td colspan="2"/></tr></tbody></table><table-wrap-foot><p>Mean&#x02009;&#x000b1;&#x02009;SEM.<sup>&#x0222e;</sup>tested by logarithmic transformation, <italic>P</italic>
<sup><italic>a</italic></sup>, values derived from independent <italic>t</italic>-test in baseline. <italic>P</italic>
<sup><italic>b</italic></sup>, values derived from independent <italic>t</italic>-test in follow-up. <italic>P</italic>
<sup><italic>c</italic></sup>, values derived from independent <italic>t</italic>-test in changed value. <italic>P</italic>
<sup><italic>d</italic></sup>, values derived from independent <italic>t</italic>-test in changed value after adjusting for baseline. <sup><italic>*</italic></sup>
<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup><italic>**</italic></sup>
<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup><italic>***</italic></sup>
<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 derived from paired <italic>t</italic>-test. PBMC, peripheral blood mononuclear cell; AUC, area under the curve; PUFA/SFA, polyunsaturated-to-saturated fatty acids ratio</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>Fasting glucose, insulin, and malondialdehyde</title><p>At the end of the study, glucose, HbA<sub>1c</sub>, and MDA concentrations significantly increased in the control group, whereas glucose, glucose AUC (area under the curve), HbA<sub>1c</sub>, HOMA-IR, insulin, and MDA significantly decreased in the whole-grain group (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Changes in glucose, glucose AUC, HbA<sub>1c</sub>, HOMA-IR, and MDA in the whole-grain group were significantly different from those in the control group before and after adjusting for baseline levels. Post-treatment glucose, HOMA-IR, and MDA in the whole-grain group were significantly lower than those in the control group (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec15"><title>Plasma ox-LDL, LDL particle size, Lp-PLA<sub>2</sub> activity in plasma and unstimulated PBMC</title><p>At the end of the study, the whole-grain group had lower ox-LDL and Lp-PLA<sub>2</sub> activity in PBMC and larger LDL particle size, whereas the control group had higher Lp-PLA<sub>2</sub> activity in PBMC (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). These changes in ox-LDL, LDL particle size, plasma Lp-PLA<sub>2</sub> activity, and PBMC Lp-PLA<sub>2</sub> activity in the whole-grain group were significantly different from those in the control group before and after adjusting for baseline levels. The post-treatment whole-grain group had lower ox-LDL and PBMC Lp-PLA<sub>2</sub> activity, and larger LDL particle size than control group (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec16"><title>Metabolic profiling of PBMC and plasma using UPLC-LTQ-orbitrap MS</title><sec id="Sec17"><title>Nontargeted metabolic pattern analysis</title><p>MS data of PBMC and plasma metabolites obtained at baseline and follow-up were analyzed with PLS-DA score scatter plot for the following two combinations: 1) control and whole-grain groups at baseline, control group at follow-up, and whole-grain group at follow-up (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, PBMC; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>, plasma); and 2) control and whole-grain groups at follow-up (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>, PBMC; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>, plasma). The PBMC metabolite PLS-DA score scatter plot showed distinct clustering and clear separation for the following subjects: control and whole-grain groups at baseline, control group at follow-up, and whole-grain group at follow-up [<italic>R</italic><sup>2</sup><italic>X</italic>(cum)&#x02009;=&#x02009;0.124, <italic>R</italic><sup>2</sup><italic>Y</italic>(cum)&#x02009;=&#x02009;0.34, <italic>Q</italic><sup>2</sup><italic>Y</italic>(cum)&#x02009;=&#x02009;0.218] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). These distinct clusters indicate that PBMC profiling detects metabolic changes induced by dietary intervention. The PBMC metabolite PLS-DA score scatter plot showed distinct clustering for control and whole-grain groups at follow-up [<italic>R</italic><sup><italic>2</italic></sup><italic>X</italic>(cum)&#x02009;=&#x02009;0.125, <italic>R</italic><sup><italic>2</italic></sup><italic>Y</italic>(cum)&#x02009;=&#x02009;0.809, <italic>Q</italic><sup><italic>2</italic></sup><italic>Y</italic>(cum)&#x02009;=&#x02009;0.525] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Identification of PBMC and plasma metabolites that were significantly altered at 12-week follow-up. <bold>a</bold> Partial least squares discriminant analysis score scatter plot (PLS-DA score scatter plot) of PBMC metabolites at baseline (<italic>n</italic>&#x02009;=&#x02009;80), whole-grain group at follow-up (<italic>n</italic>&#x02009;=&#x02009;40), and control group at follow-up (<italic>n</italic>&#x02009;=&#x02009;40). <bold>b</bold> PLS-DA score scatter plot of PBMC metabolites for whole-grain group at follow-up (<italic>n</italic>&#x02009;=&#x02009;40) and control group at follow-up (<italic>n</italic>&#x02009;=&#x02009;40). <bold>c</bold> PLS-DA PLS-DA score scatter plot of plasma metabolites at baseline (<italic>n</italic>&#x02009;=&#x02009;80), whole-grain group at follow-up (<italic>n</italic>&#x02009;=&#x02009;40), and control group at follow-up (<italic>n</italic>&#x02009;=&#x02009;40). <bold>d</bold> PLS-DA score scatter plot of plasma metabolites for whole-grain group at follow-up (<italic>n</italic>&#x02009;=&#x02009;40) and control group at follow-up (<italic>n</italic>&#x02009;=&#x02009;40)</p></caption><graphic xlink:href="12986_2016_63_Fig1_HTML" id="MO1"/></fig></p><p>The plasma metabolite PLS-DA score scatter plot were not as clearly clustered as those for PBMC metabolites [<italic>R</italic><sup>2</sup><italic>X</italic>(cum)&#x02009;=&#x02009;0.124, <italic>R</italic><sup>2</sup><italic>Y</italic>(cum)&#x02009;=&#x02009;0.376, <italic>Q</italic><sup>2</sup><italic>Y</italic>(cum)&#x02009;=&#x02009;0.127] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>). For control and whole-grain groups at follow-up, the plasma metabolite PLS-DA score scatter plot were not as clearly clustered as those for PBMC metabolites [<italic>R</italic><sup><italic>2</italic></sup><italic>X</italic>(cum)&#x02009;=&#x02009;0.201, <italic>R</italic><sup><italic>2</italic></sup><italic>Y</italic>(cum)&#x02009;=&#x02009;0.704, <italic>Q</italic><sup><italic>2</italic></sup><italic>Y</italic>(cum)&#x02009;=&#x02009;0.414] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>). To identify metabolites that differentially determined data at baseline and follow-up, <italic>S</italic>-plots of p(1) and p(corr) (1) were generated using centroid scaling. The <italic>S</italic>-plots revealed that metabolites with higher or lower p(corr) values more clearly discriminated between the two groups.</p></sec><sec id="Sec18"><title>Identification of PBMC metabolites</title><p>Of 1,923 PBMC metabolites, those that correlated with separation between the groups were identified by the variable important in the projection (VIP) parameter; VIP values &#x0003e;1.0 were highly relevant for group differences. 51 metabolites had VIP &#x0003e;1.0; 10 of these were previously identified and 41 were unknown. Those 10 PBMC metabolites at baseline and follow-up are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. There were no significant differences in baseline metabolites between two groups. After follow-up, the control group showed significant changes in six PBMC metabolite levels, whereas the whole-grain group showed significant changes in seven PBMC metabolite levels (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Identification of PBMC metabolites at baseline and 12-week follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3">Metabolite</th><th rowspan="3">Formula [M&#x02009;+&#x02009;H]<sup>+</sup>
</th><th rowspan="3">Exact mass (M&#x02009;+&#x02009;H)</th><th colspan="4">Normalized peak intensity</th><th colspan="3">Variable important in the projection</th></tr><tr><th colspan="2">Control group (<italic>n</italic>&#x02009;=&#x02009;40)</th><th colspan="2">Whole-grain group (<italic>n</italic>&#x02009;=&#x02009;40)</th><th colspan="2">Baseline vs. follow-up</th><th>12-weeks</th></tr><tr><th>Baseline</th><th>Follow-up</th><th>Baseline</th><th>Follow-up</th><th>Control</th><th>Whole-grain</th><th>Control vs. whole-grain</th></tr></thead><tbody><tr><td>Cyclopentanone dimethylhydrazone</td><td>C<sub>7</sub>H<sub>14</sub>N<sub>2</sub>
</td><td>127.1235</td><td>82,551&#x02009;&#x000b1;&#x02009;21,507</td><td>101,931&#x02009;&#x000b1;&#x02009;26,693<sup><italic>*</italic></sup>
</td><td>43,192&#x02009;&#x000b1;&#x02009;11,728</td><td>51,504&#x02009;&#x000b1;&#x02009;14,505<sup><italic>*</italic></sup>
</td><td>0.0722</td><td>0.1523</td><td>1.0119</td></tr><tr><td>L-Pyroglutamic acid</td><td>C<sub>5</sub>H<sub>7</sub>NO<sub>3</sub>
</td><td>130.0504</td><td>2,410,045&#x02009;&#x000b1;&#x02009;108,001</td><td>2,075,511&#x02009;&#x000b1;&#x02009;48,362<sup><italic>*</italic></sup>
</td><td>2,455,521&#x02009;&#x000b1;&#x02009;70,667</td><td>2,484,381&#x02009;&#x000b1;&#x02009;103,907<sup><italic>&#x02020;&#x02020;</italic></sup>
</td><td>0.1241</td><td>3.9771</td><td>2.6550</td></tr><tr><td>L-Leucine</td><td>C<sub>6</sub>H<sub>13</sub>NO<sub>2</sub>
</td><td>132.1025</td><td>7,884,178&#x02009;&#x000b1;&#x02009;309,297</td><td>7,922,462&#x02009;&#x000b1;&#x02009;251,819</td><td>8,253,845&#x02009;&#x000b1;&#x02009;170,803</td><td>7,531,331&#x02009;&#x000b1;&#x02009;171,144<sup><italic>**</italic></sup>
</td><td>1.8209</td><td>3.1661</td><td>5.0363</td></tr><tr><td>Change</td><td/><td/><td colspan="2">38,283&#x02009;&#x000b1;&#x02009;198,486</td><td colspan="2">&#x02212;722,514&#x02009;&#x000b1;&#x02009;145,341<sup><italic>&#x02021;</italic></sup>
</td><td/><td/><td/></tr><tr><td>L-Phenylalanine</td><td>C<sub>9</sub>H<sub>11</sub>NO<sub>2</sub>
</td><td>166.0868</td><td>2,880,509&#x02009;&#x000b1;&#x02009;113,266</td><td>2,755,872&#x02009;&#x000b1;&#x02009;75,646</td><td>2,825,355&#x02009;&#x000b1;&#x02009;101,371</td><td>2,761,323&#x02009;&#x000b1;&#x02009;56,360</td><td>0.5962</td><td>0.6567</td><td>1.1474</td></tr><tr><td>Dihydrobiopterin</td><td>C<sub>9</sub>H<sub>13</sub>N5O<sub>3</sub>
</td><td>239.1018</td><td>432,360&#x02009;&#x000b1;&#x02009;23,845</td><td>335,279&#x02009;&#x000b1;&#x02009;14,924<sup><italic>***</italic></sup>
</td><td>427,487&#x02009;&#x000b1;&#x02009;16,797</td><td>383,280&#x02009;&#x000b1;&#x02009;15,727<sup><italic>*</italic></sup>
</td><td>0.4537</td><td>1.2616</td><td>0.4680</td></tr><tr><td>Palmitic amide</td><td>C<sub>16</sub>H<sub>33</sub>NO</td><td>256.2640</td><td>354,492&#x02009;&#x000b1;&#x02009;50,930</td><td>330,909&#x02009;&#x000b1;&#x02009;44,809</td><td>490,272&#x02009;&#x000b1;&#x02009;84,177</td><td>172,851&#x02009;&#x000b1;&#x02009;26,551<sup><italic>**,&#x02020;</italic></sup>
</td><td>2.7281</td><td>0.1468</td><td>2.0394</td></tr><tr><td>Ribothymidine</td><td>C<sub>10</sub>H<sub>14</sub>N<sub>2</sub>O<sub>6</sub>
</td><td>258.0930</td><td>302,320&#x02009;&#x000b1;&#x02009;22,108</td><td>239,902&#x02009;&#x000b1;&#x02009;12,851<sup><italic>**</italic></sup>
</td><td>322,971&#x02009;&#x000b1;&#x02009;16,498</td><td>311,114&#x02009;&#x000b1;&#x02009;19,898<sup><italic>&#x02020;</italic></sup>
</td><td>0.0730</td><td>0.5966</td><td>1.3107</td></tr><tr><td>Oleamide</td><td>C<sub>18</sub>H<sub>35</sub>NO</td><td>282.2797</td><td>2,676,408&#x02009;&#x000b1;&#x02009;412,881</td><td>3,257,688&#x02009;&#x000b1;&#x02009;511,380</td><td>3,697,245&#x02009;&#x000b1;&#x02009;621,193</td><td>1,491,246&#x02009;&#x000b1;&#x02009;235,475<sup><italic>*,&#x02020;</italic></sup>
</td><td>18.4793</td><td>8.3202</td><td>22.5845</td></tr><tr><td>Change</td><td/><td/><td colspan="2">581,279&#x02009;&#x000b1;&#x02009;634,410</td><td colspan="2">&#x02212;2,205,998&#x02009;&#x000b1;&#x02009;651,404<sup><italic>&#x02021;</italic></sup>
</td><td/><td/><td/></tr><tr><td>LysoPC(16:0)</td><td>C<sub>24</sub>H<sub>50</sub>NO<sub>7</sub>P</td><td>496.3403</td><td>414,438&#x02009;&#x000b1;&#x02009;44,544</td><td>645,199&#x02009;&#x000b1;&#x02009;57,544<sup><italic>*</italic></sup>
</td><td>549,155&#x02009;&#x000b1;&#x02009;59,016</td><td>383,399&#x02009;&#x000b1;&#x02009;35,718<sup><italic>*,&#x02020;&#x02020;</italic></sup>
</td><td>2.7864</td><td>2.8925</td><td>3.5066</td></tr><tr><td>Change</td><td/><td/><td colspan="2">230,762&#x02009;&#x000b1;&#x02009;72,860</td><td colspan="2">&#x02212;165,756&#x02009;&#x000b1;&#x02009;63,955<sup><italic>&#x02021;&#x02021;</italic></sup>
</td><td/><td/><td/></tr><tr><td>LysoPC(18:0)</td><td>C<sub>26</sub>H<sub>54</sub>NO<sub>7</sub>P</td><td>524.3716</td><td>285,044&#x02009;&#x000b1;&#x02009;26,648</td><td>423,718&#x02009;&#x000b1;&#x02009;34,129<sup><italic>**</italic></sup>
</td><td>364,186&#x02009;&#x000b1;&#x02009;33,732</td><td>262,585&#x02009;&#x000b1;&#x02009;23,409<sup><italic>*,&#x02020;&#x02020;</italic></sup>
</td><td>1.5197</td><td>1.7796</td><td>2.0579</td></tr><tr><td>Change</td><td/><td/><td colspan="2">138,674&#x02009;&#x000b1;&#x02009;40,222</td><td colspan="2">&#x02212;101,601&#x02009;&#x000b1;&#x02009;42,602<sup><italic>&#x02021;&#x02021;</italic></sup>
</td><td/><td/><td/></tr></tbody></table><table-wrap-foot><p>Mean&#x02009;&#x000b1;&#x02009;SEM. <sup><italic>*</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup><italic>**</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup><italic>***</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.001 derived from paired <italic>t</italic>-test. <sup><italic>&#x02020;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup><italic>&#x02020;&#x02020;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup><italic>&#x02020;&#x02020;&#x02020;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.001 derived from independent <italic>t</italic>-test in follow-up. <sup><italic>&#x02021;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup><italic>&#x02021;&#x02021;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup><italic>&#x02021;&#x02021;&#x02021;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.001 derived from changed values between control and whole-grain groups</p></table-wrap-foot></table-wrap></p><p>We compared PBMC metabolite changes between two groups. The whole-grain group had greater reductions in L-leucine (<italic>q</italic>&#x02009;=&#x02009;0.031), oleamide (<italic>q&#x02009;=</italic>&#x02009;0.032), lysoPC (16:0) (<italic>q&#x02009;=</italic>&#x02009;0.003), and lysoPC (18:0) (<italic>q&#x02009;=</italic>&#x02009;0.003) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). At follow-up, the whole-grain group had higher peak intensities of L-pyroglutamic acid and ribothymidine, and lower peak intensities of palmitic amide, oleamide, and lysoPCs, compared with those of the control group (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p></sec><sec id="Sec19"><title>Identification of plasma metabolites</title><p>Of 4,121 plasma metabolites, those that correlated with separation between the groups were selected by VIP &#x0003e;1.0. 122 plasma metabolites were selected; 20 were previously identified and 102 were unknown (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). There were no significant differences in baseline between two groups. After follow-up, C17 sphinganine significantly increased in the control group, also, there were no significant differences in metabolites between two groups, and no significant differences in metabolite changes with respect to baseline (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Identification of plasma metabolites at baseline and 12-week follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3">Metabolite</th><th rowspan="3">Formula [M&#x02009;+&#x02009;H]<sup>+</sup>
</th><th rowspan="3">Exact mass (M&#x02009;+&#x02009;H)</th><th colspan="4">Normalized peak intensity</th><th colspan="3">Variable important in the projection</th></tr><tr><th colspan="2">Control group (<italic>n</italic>&#x02009;=&#x02009;40)</th><th colspan="2">Whole-grain group (<italic>n</italic>&#x02009;=&#x02009;40)</th><th colspan="2">Baseline vs. follow-up</th><th>12-weeks</th></tr><tr><th>Baseline</th><th>Follow-up</th><th>Baseline</th><th>Follow-up</th><th>Control</th><th>Whole-grain</th><th>Control vs. whole grain</th></tr></thead><tbody><tr><td>L-Valine</td><td>C<sub>5</sub>H<sub>11</sub>NO<sub>2</sub>
</td><td>118.0868</td><td>1,338,114&#x02009;&#x000b1;&#x02009;39,666</td><td>1,323,676&#x02009;&#x000b1;&#x02009;36,213</td><td>1,328,470&#x02009;&#x000b1;&#x02009;41,793</td><td>1,376,655&#x02009;&#x000b1;&#x02009;34,768</td><td>0.7807</td><td>0.1901</td><td>1.0144</td></tr><tr><td>L-Leucine</td><td>C<sub>6</sub>H<sub>13</sub>NO<sub>2</sub>
</td><td>132.1025</td><td>3,130,607&#x02009;&#x000b1;&#x02009;99,839</td><td>3,098,031&#x02009;&#x000b1;&#x02009;98,593</td><td>3,130,777&#x02009;&#x000b1;&#x02009;107,368</td><td>3,166,315&#x02009;&#x000b1;&#x02009;85,278</td><td>0.4904</td><td>0.5781</td><td>0.7853</td></tr><tr><td>L-Phenylalanine</td><td>C<sub>9</sub>H<sub>11</sub>NO<sub>2</sub>
</td><td>166.0868</td><td>1,984,169&#x02009;&#x000b1;&#x02009;49,821</td><td>1,914,567&#x02009;&#x000b1;&#x02009;45,393</td><td>1,997,467&#x02009;&#x000b1;&#x02009;84,582</td><td>1,975,319&#x02009;&#x000b1;&#x02009;41,491</td><td>0.6137</td><td>1.1072</td><td>0.7382</td></tr><tr><td>Oleamide</td><td>C<sub>18</sub>H<sub>35</sub>NO</td><td>282.2797</td><td>11,074,949&#x02009;&#x000b1;&#x02009;815,519</td><td>11,182,173&#x02009;&#x000b1;&#x02009;1,054,856</td><td>11,348,184&#x02009;&#x000b1;&#x02009;805,164</td><td>12,102,398&#x02009;&#x000b1;&#x02009;709,965</td><td>8.4316</td><td>19.2720</td><td>6.6270</td></tr><tr><td>C17 Sphinganine</td><td>C<sub>17</sub>H<sub>37</sub>NO<sub>2</sub>
</td><td>288.2903</td><td>323,013&#x02009;&#x000b1;&#x02009;20,549</td><td>441,137&#x02009;&#x000b1;&#x02009;24,748<sup><italic>*</italic></sup>
</td><td>333,258&#x02009;&#x000b1;&#x02009;29,775</td><td>355,950&#x02009;&#x000b1;&#x02009;25,250</td><td>0.9135</td><td>1.3462</td><td>0.1114</td></tr><tr><td>(4E,8E,10E-d18:3) Sphingosine</td><td>C<sub>18</sub>H<sub>33</sub>NO<sub>2</sub>
</td><td>296.2590</td><td>420,731&#x02009;&#x000b1;&#x02009;59,507</td><td>832,979&#x02009;&#x000b1;&#x02009;152,996</td><td>608,061&#x02009;&#x000b1;&#x02009;81,037</td><td>754,737&#x02009;&#x000b1;&#x02009;66,758</td><td>1.5120</td><td>8.8050</td><td>2.2736</td></tr><tr><td>Anandamide (18:4, n-3)</td><td>C<sub>20</sub>H<sub>33</sub>NO<sub>2</sub>
</td><td>320.2590</td><td>170,194&#x02009;&#x000b1;&#x02009;28,584</td><td>237,343&#x02009;&#x000b1;&#x02009;31,518</td><td>209,059&#x02009;&#x000b1;&#x02009;26,262</td><td>213,643&#x02009;&#x000b1;&#x02009;16,101</td><td>0.1156</td><td>1.4954</td><td>0.5840</td></tr><tr><td>LysoPC (14:0)</td><td>C<sub>22</sub>H<sub>46</sub>NO<sub>7</sub>P</td><td>468.3090</td><td>480,474&#x02009;&#x000b1;&#x02009;33,898</td><td>503,684&#x02009;&#x000b1;&#x02009;38,015</td><td>625,962&#x02009;&#x000b1;&#x02009;45,904</td><td>537,767&#x02009;&#x000b1;&#x02009;45,983</td><td>1.5352</td><td>0.7142</td><td>0.2242</td></tr><tr><td>LysoPC (16:1)</td><td>C<sub>24</sub>H<sub>48</sub>NO<sub>7</sub>P</td><td>494.3247</td><td>1,133,250&#x02009;&#x000b1;&#x02009;77,052</td><td>1,033,013&#x02009;&#x000b1;&#x02009;69,288</td><td>1,261,066&#x02009;&#x000b1;&#x02009;78,064</td><td>1,127,811&#x02009;&#x000b1;&#x02009;88,549</td><td>2.3243</td><td>1.4177</td><td>1.0354</td></tr><tr><td>LysoPC (16:0)</td><td>C<sub>24</sub>H<sub>50</sub>NO<sub>7</sub>P</td><td>496.3403</td><td>15,953,932&#x02009;&#x000b1;&#x02009;573,566</td><td>15,910,457&#x02009;&#x000b1;&#x02009;684,453</td><td>16,830,932&#x02009;&#x000b1;&#x02009;686,817</td><td>15,967,767&#x02009;&#x000b1;&#x02009;537,944</td><td>15.3974</td><td>7.7607</td><td>4.7470</td></tr><tr><td>LysoPC (17:0)</td><td>C<sub>25</sub>H<sub>52</sub>NO<sub>7</sub>P</td><td>510.3560</td><td>689,578&#x02009;&#x000b1;&#x02009;58,089</td><td>710,335&#x02009;&#x000b1;&#x02009;73,384</td><td>758,848&#x02009;&#x000b1;&#x02009;49,685</td><td>733,637&#x02009;&#x000b1;&#x02009;53,343</td><td>0.5841</td><td>1.3389</td><td>0.1217</td></tr><tr><td>LysoPC (18:3)</td><td>C<sub>26</sub>H<sub>48</sub>NO<sub>7</sub>P</td><td>518.3247</td><td>620,814&#x02009;&#x000b1;&#x02009;20,714</td><td>591,900&#x02009;&#x000b1;&#x02009;19,836</td><td>658,460&#x02009;&#x000b1;&#x02009;22,577</td><td>675,799&#x02009;&#x000b1;&#x02009;31,645</td><td>0.1217</td><td>0.3985</td><td>1.1643</td></tr><tr><td>LysoPC (18:2)</td><td>C<sub>26</sub>H<sub>50</sub>NO<sub>7</sub>P</td><td>520.3403</td><td>6,388,637&#x02009;&#x000b1;&#x02009;262,115</td><td>6,025,486&#x02009;&#x000b1;&#x02009;300,959</td><td>6,617,717&#x02009;&#x000b1;&#x02009;260,021</td><td>6,878,238&#x02009;&#x000b1;&#x02009;274,508</td><td>2.2535</td><td>4.8170</td><td>15.1889</td></tr><tr><td>LysoPC (18:1)</td><td>C<sub>26</sub>H<sub>52</sub>NO<sub>7</sub>P</td><td>522.3560</td><td>5,375,808&#x02009;&#x000b1;&#x02009;229,038</td><td>5,364,828&#x02009;&#x000b1;&#x02009;250,194</td><td>5,593,899&#x02009;&#x000b1;&#x02009;214,117</td><td>5,425,134&#x02009;&#x000b1;&#x02009;241,245</td><td>4.2976</td><td>3.7059</td><td>4.2779</td></tr><tr><td>LysoPC (18:0)</td><td>C<sub>26</sub>H<sub>54</sub>NO<sub>7</sub>P</td><td>524.3716</td><td>5,661,866&#x02009;&#x000b1;&#x02009;195,118</td><td>5,610,496&#x02009;&#x000b1;&#x02009;261,241</td><td>5,976,007&#x02009;&#x000b1;&#x02009;255,107</td><td>5,830,224&#x02009;&#x000b1;&#x02009;224,489</td><td>2.5863</td><td>3.3556</td><td>5.4463</td></tr><tr><td>LysoPC (20:5)</td><td>C<sub>28</sub>H<sub>48</sub>NO<sub>7</sub>P</td><td>542.3247</td><td>771,884&#x02009;&#x000b1;&#x02009;61,530</td><td>784,374&#x02009;&#x000b1;&#x02009;53,112</td><td>997,008&#x02009;&#x000b1;&#x02009;89,800</td><td>876,925&#x02009;&#x000b1;&#x02009;59,723</td><td>2.1218</td><td>0.4055</td><td>1.2595</td></tr><tr><td>LysoPC (20:4)</td><td>C<sub>28</sub>H<sub>50</sub>NO<sub>7</sub>P</td><td>544.3403</td><td>2,512,566&#x02009;&#x000b1;&#x02009;118,266</td><td>2,294,343&#x02009;&#x000b1;&#x02009;118,562</td><td>2,188,892&#x02009;&#x000b1;&#x02009;126,719</td><td>1,958,744&#x02009;&#x000b1;&#x02009;83,560</td><td>2.9839</td><td>3.3959</td><td>6.5629</td></tr><tr><td>LysoPC (22:6)</td><td>C<sub>30</sub>H<sub>50</sub>NO<sub>7</sub>P</td><td>568.3403</td><td>1,268,789&#x02009;&#x000b1;&#x02009;89,205</td><td>1,160,444&#x02009;&#x000b1;&#x02009;72,253</td><td>1,322,936&#x02009;&#x000b1;&#x02009;96,792</td><td>1,153,481&#x02009;&#x000b1;&#x02009;79,319</td><td>1.8183</td><td>1.6819</td><td>0.2714</td></tr><tr><td>SM (d18:0/16:1)</td><td>C<sub>39</sub>H<sub>79</sub>N<sub>2</sub>O<sub>6</sub>P</td><td>703.5754</td><td>918,463&#x02009;&#x000b1;&#x02009;110,095</td><td>628,987&#x02009;&#x000b1;&#x02009;81,863</td><td>1,046,537&#x02009;&#x000b1;&#x02009;118,533</td><td>1,088,608&#x02009;&#x000b1;&#x02009;142,939</td><td>0.9346</td><td>4.2113</td><td>7.9088</td></tr><tr><td>Lactosylceramide (d18:1/12:0)</td><td>C<sub>42</sub>H<sub>79</sub>NO<sub>13</sub>
</td><td>806.5630</td><td>5,977,825&#x02009;&#x000b1;&#x02009;630,100</td><td>8,134,712&#x02009;&#x000b1;&#x02009;703,408</td><td>6,832,476&#x02009;&#x000b1;&#x02009;741,718</td><td>5,908,934&#x02009;&#x000b1;&#x02009;712,523</td><td>4.8718</td><td>8.3007</td><td>5.9197</td></tr><tr><td>
<sup>1</sup>PCs</td><td/><td/><td>44,523,937&#x02009;&#x000b1;&#x02009;2,514,233</td><td>44,154,177&#x02009;&#x000b1;&#x02009;1,968,873</td><td>43,454,754&#x02009;&#x000b1;&#x02009;2,366,214</td><td>50,137,749&#x02009;&#x000b1;&#x02009;2,118,552</td><td/><td/><td/></tr></tbody></table><table-wrap-foot><p>Mean&#x02009;&#x000b1;&#x02009;SEM. <sup><italic>*</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup><italic>**</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup><italic>***</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.001 derived from paired <italic>t</italic>-test. <sup><italic>&#x02020;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup><italic>&#x02020;&#x02020;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup><italic>&#x02020;&#x02020;&#x02020;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.001 derived from independent <italic>t</italic>-test in follow-up. <sup><italic>&#x02021;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup><italic>&#x02021;&#x02021;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup><italic>&#x02021;&#x02021;&#x02021;</italic></sup>
<italic>q</italic>&#x02009;&#x0003c;&#x02009;0.001 derived from changed values between control and whole-grain groups. <sup>1</sup>PCs were detected by Orbitrap MS; therefore, all detected PC amounts were combined. SM, sphingomyelin</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec20"><title>Correlations among fasting glucose, plasma and PBMC Lp-PLA<sub>2</sub> activities, biochemical parameters, and major PBMC metabolites</title><p>The correlation matrix of changes in glucose, Lp-PLA<sub>2</sub> activities in plasma and PBMC, biochemical parameters, and major PBMC metabolites was computed (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Analysis of metabolic changes including all subjects identified the following correlations: glucose correlated positively with insulin, HOMA-IR, plasma Lp-PLA<sub>2</sub> activity (<italic>r</italic>&#x02009;=&#x02009;0.454, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), MDA, ox-LDL, Lp-PLA<sub>2</sub> in PBMC (<italic>r</italic>&#x02009;=&#x02009;0.511, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), glucose AUC, C-peptide, HbA<sub>1c</sub>, and PBMC lysoPCs after adjusting for age, gender, BMI, smoking, and drinking. After adjusting for confounding variables, plasma Lp-PLA<sub>2</sub> activity correlated positively with glucose, HOMA-IR, ox-LDL, Lp-PLA<sub>2</sub> activity in PBMC (<italic>r</italic>&#x02009;=&#x02009;0.516, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), glucose AUC, PBMC palmitic amide, and PBMC oleamide. After adjusting for confounding variables, PBMC Lp-PLA<sub>2</sub> activity correlated positively with glucose, HOMA-IR, plasma Lp-PLA<sub>2</sub> activity, ox-LDL, PBMC L-leucine, PBMC oleamide, PBMC lysoPCs, and correlated negatively with LDL particle size (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Correlation matrix for changes in biochemical characteristics and PBMC metabolites in total subjects. Supervised hierarchical clustering identifies the most important 10 metabolites and 9 biochemical characteristics. Correlations were obtained by deriving Spearman correlation coefficients. <italic>Red</italic>, positive correlation. <italic>Purple</italic>, negative correlation</p></caption><graphic xlink:href="12986_2016_63_Fig2_HTML" id="MO2"/></fig></p></sec></sec><sec id="Sec21"><title>Discussion</title><p>We identified four PBMC metabolites that had statistically significant differences after dietary intervention, including L-leucine, oleamide, lysoPC (16:0), and lysoPC (18:0); however, there were no significant differences in plasma metabolites after dietary intervention. These aspects of results were also shown in both subjects with prediabetes and T2D, respectively. PBMCs may be a useful tool for nutrigenomics and understanding the pathophysiology of chronic disease due to their active metabolism [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. These results identify PBMC metabolites as powerful metabolomics tools to detect diet-induced metabolic changes.</p><p>Improving glycemic control in the whole-grain group decreases ox-LDL, and reduces PBMC Lp-PLA<sub>2</sub> activity and PBMC lysoPCs. A strong correlation between PBMC Lp-PLA<sub>2</sub> activity and ox-LDL, but not LDL-cholesterol, is consistent with a previous report of a direct effect of ox-LDL on Lp-PLA<sub>2</sub> expression in THP-1 monocytes [<xref ref-type="bibr" rid="CR16">16</xref>]. Ox-LDL may upregulate PBMC Lp-PLA<sub>2</sub> expression in smokers [<xref ref-type="bibr" rid="CR17">17</xref>]. Ox-phospholipids in LDL particles are hydrolyzed by Lp-PLA<sub>2</sub> at the <italic>sn</italic>-2 position to produce bioactive ox-FFAs and lysoPCs. Only 1&#x02009;&#x02212;&#x02009;5&#x000a0;% of the total non-ox-LDL PC content is lysoPC; however, up to 40&#x02009;&#x02212;&#x02009;50&#x000a0;% of LDL PC is converted to lysoPC during LDL oxidation [<xref ref-type="bibr" rid="CR18">18</xref>]. This study identified strongly positive correlations among ox-LDL, PBMC Lp-PLA<sub>2</sub> activity, PBMC lysoPCs, which may indicate that ox-LDL and PBMC Lp-PLA<sub>2</sub> activity are major determinants of PBMC lysoPC levels.</p><p>A negative correlation between PBMC Lp-PLA<sub>2</sub> activities, PBMC lysoPCs with LDL particle size is consistent with a previous report of Lp-PLA<sub>2</sub> binding preference for small dense LDL [<xref ref-type="bibr" rid="CR19">19</xref>]. This study and other work [<xref ref-type="bibr" rid="CR6">6</xref>] reported positive correlations among glucose, PBMC Lp-PLA<sub>2</sub> activity, and plasma Lp-PLA<sub>2</sub> activity. A strongly positive correlation between PBMC and plasma Lp-PLA<sub>2</sub> activities also is observed in healthy subjects [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In a porcine diabetes model, PBMC Lp-PLA<sub>2</sub> expression is upregulated in the presence of glycation end products [<xref ref-type="bibr" rid="CR21">21</xref>]. Increases in circulating Lp-PLA<sub>2</sub> activity and increased ox-LDL levels in hypercholesterolemic pigs are primarily due to plaque macrophages [<xref ref-type="bibr" rid="CR22">22</xref>]. These results indicate that the primary sources of plasma Lp-PLA<sub>2</sub> are plaque macrophages [<xref ref-type="bibr" rid="CR22">22</xref>] and PBMC [<xref ref-type="bibr" rid="CR17">17</xref>]. This could explain our observations of lower plasma Lp-PLA<sub>2</sub> activity changes compared with that of PBMC Lp-PLA<sub>2</sub> activity, and no significant differences in plasma metabolite changes between two groups.</p><p>Reduced Lp-PLA<sub>2</sub> activity in plasma and PBMC in the whole-grain group could be a marker of metabolic changes induced by increased consumption of protein relative to carbohydrate. Diet composition is an important factor in inflammatory processes of blood cells [<xref ref-type="bibr" rid="CR23">23</xref>]. A study of macronutrient composition determined that increasing dietary protein from 19&#x000a0;% energy intake to 30&#x000a0;% yielded immediate and persistent downregulation of immunological genes in PBMCs [<xref ref-type="bibr" rid="CR9">9</xref>]. Replacing 5&#x000a0;% of energy from carbohydrates with energy from protein and measured a 2.2&#x000a0;nmol/min/mL reduction in Lp-PLA<sub>2</sub> activity that was independent of other changes in lipid profiles [<xref ref-type="bibr" rid="CR5">5</xref>]. Our study replaced 7&#x000a0;% of energy from carbohydrate with approximately 4&#x000a0;% energy from protein and 3&#x000a0;% energy from fat.</p><p>Whole grains, legumes, and vegetables contain many antioxidants, vitamins, minerals, and phytochemicals [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Antioxidants slow the oxidation rate of reduced substrates [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Soybean phytochemicals reduce lipid peroxidation <italic>in vivo</italic> and attenuate LDL oxidation [<xref ref-type="bibr" rid="CR27">27</xref>]. Our observed changes in glucose and HOMA-IR strongly correlated with changes in MDA and ox-LDL in patients with prediabetes or T2D, consistent with a previous report [<xref ref-type="bibr" rid="CR28">28</xref>]. We observed positive correlation between changes in HOMA-IR and PBMC L-leucine, but not plasma L-leucine. This may be due to a negligible effect of PBMC L-leucine on plasma L-leucine, or the 12-week dietary intervention may not be long enough to change plasma L-leucine. The whole-grain group also had greater reduction in PBMC oleamide, but not in plasma, compared with control group. We identified PBMC oleamide (VIP&#x02009;=&#x02009;22.5845) as the most important metabolite for evaluating differences between two groups at the end of the study. Recently, Ha et al. [<xref ref-type="bibr" rid="CR29">29</xref>] identified plasma oleamide as the most important metabolite for distinguishing nondiabetic from diabetic males. Therefore, positive correlations between changes in PBMC oleamide, Lp-PLA<sub>2</sub>, PBMC palmitic amide, and PBMC lysoPCs observed in our study could be partly due to dietary-induced effects on blood cell inflammatory processes [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>This study detected many metabolic markers using UPLC-LTQ-Orbitrap MS, but most are currently unidentified. Endogenous biomolecule databases for use with LC-MS&#x02009;&#x02212;&#x02009;based metabolomics research are still under construction [<xref ref-type="bibr" rid="CR30">30</xref>]. Despite this limitation, UPLC-LTQ-Orbitrap MS metabolomics and multivariate data analysis identified greater reductions in PBMC L-leucine, PBMC oleamide, PBMC lysoPCs in the whole-grain group than control group; however, there were no significant differences in plasma metabolites between two groups.</p></sec><sec id="Sec22"><title>Conclusion</title><p>This study demonstrates that replacing refined rice with whole grains and legumes induced greater differences in PBMC Lp-PLA<sub>2</sub> activity and metabolites than in plasma metabolites in nonobese patients with prediabetes or newly-diagnosed T2D. Therefore, consumption of minimally refined grains, legumes, and vegetables should be recommended to control glucose metabolism and reduce cardiovascular risk factors in patients with IFG, IGT, or newly-diagnosed T2D.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>Lp-PLA<sub>2</sub></term><def><p>Lipoprotein-associated phospholipase A<sub>2</sub></p></def></def-item><def-item><term>T2D</term><def><p>Type-2 diabetes</p></def></def-item><def-item><term>PBMC</term><def><p>Peripheral blood mononuclear cell</p></def></def-item><def-item><term>IFG</term><def><p>Impaired fasting glucose</p></def></def-item><def-item><term>IGT</term><def><p>Impaired glucose tolerance</p></def></def-item><def-item><term>BMI</term><def><p>Body mass index</p></def></def-item><def-item><term>BP</term><def><p>Blood pressure</p></def></def-item><def-item><term>HDL</term><def><p>High density lipoprotein</p></def></def-item><def-item><term>LDL</term><def><p>Low density lipoprotein</p></def></def-item><def-item><term>FFA</term><def><p>Free fatty acid</p></def></def-item><def-item><term>HbA<sub>1c</sub></term><def><p>Hemoglobin A<sub>1c</sub></p></def></def-item><def-item><term>IR</term><def><p>Insulin resistance</p></def></def-item><def-item><term>HOMA</term><def><p>Homeostasis-model assessment</p></def></def-item><def-item><term>FBS</term><def><p>Fetal bovine serum</p></def></def-item><def-item><term>hs-CRP</term><def><p>High-sensitivity C-reactive protein</p></def></def-item><def-item><term>MDA</term><def><p>Malondialdehyde</p></def></def-item><def-item><term>TBARS</term><def><p>Thiobarbituric acid-reactive substances</p></def></def-item><def-item><term>Ox</term><def><p>Oxidized</p></def></def-item><def-item><term>MS</term><def><p>Mass spectrometer</p></def></def-item><def-item><term>PLS-DA</term><def><p>Partial least-squares discriminant analysis</p></def></def-item><def-item><term>WHR</term><def><p>Waist-hip ratio</p></def></def-item><def-item><term>AUC</term><def><p>Area under the curve</p></def></def-item><def-item><term>VIP</term><def><p>Variable important in the projection</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>All the authors were involved in the development of the study protocol and the experimental design. GS, MK and JHY collected samples and carried out experiments. MK performed data analysis. T-SJ, S-HL and JHL reviewed data and participated in general discussion. JHL provided the research funding and wrote the manuscript. All the authors read, commented on, and contributed to the submitted manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><p>This research was supported by the Bio-Synergy Research Projects (NRF-2012M3A9C4048762) of the National Research Foundation (NRF) funded by the Ministry of Science, ICT &#x00026; Future Planning, Republic of Korea.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Statistics Korea: Causes of death statistics in 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://kostat.go.kr">http://kostat.go.kr</ext-link> (updated 23 Sep 2014).</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</collab></person-group><article-title>Report of the expert committee on the diagnosis and classification of diabetes mellitus</article-title><source>Diabetes Care</source><year>1997</year><volume>20</volume><fpage>1183</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.2337/diacare.20.7.1183</pub-id><pub-id pub-id-type="pmid">9203460</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>KG</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group><article-title>Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation</article-title><source>Diabet Med</source><year>1998</year><volume>15</volume><fpage>539</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9136(199807)15:7&#x0003c;539::AID-DIA668&#x0003e;3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">9686693</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>TL</given-names></name><name><surname>Biggs</surname><given-names>ML</given-names></name><name><surname>Kizer</surname><given-names>JR</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Hokanson</surname><given-names>JE</given-names></name><name><surname>Furberg</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the cardiovascular health study</article-title><source>J Clin Endocrinol Metab</source><year>2012</year><volume>97</volume><fpage>1695</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1210/jc.2011-3026</pub-id><pub-id pub-id-type="pmid">22399516</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatoum</surname><given-names>IJ</given-names></name><name><surname>Nelson</surname><given-names>JJ</given-names></name><name><surname>Cook</surname><given-names>NR</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name></person-group><article-title>Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease</article-title><source>Am J Clin Nutr</source><year>2010</year><volume>91</volume><fpage>786</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2009.28870</pub-id><pub-id pub-id-type="pmid">20107195</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Jeung</surname><given-names>SR</given-names></name><name><surname>Jeong</surname><given-names>TS</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D</article-title><source>J Lipid Res</source><year>2014</year><volume>55</volume><fpage>1762</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1194/jlr.M044834</pub-id><pub-id pub-id-type="pmid">24904022</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dentan</surname><given-names>C</given-names></name><name><surname>Lesnik</surname><given-names>P</given-names></name><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Ninio</surname><given-names>E</given-names></name></person-group><article-title>Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells. Relevance to the inflammatory reaction in atherogenesis</article-title><source>Eur J Biochem</source><year>1996</year><volume>236</volume><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1996.00048.x</pub-id><pub-id pub-id-type="pmid">8617285</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>EH</given-names></name><name><surname>McConnell</surname><given-names>JP</given-names></name><name><surname>Lennon</surname><given-names>RJ</given-names></name><name><surname>Barsness</surname><given-names>GW</given-names></name><name><surname>Pumper</surname><given-names>G</given-names></name><name><surname>Hartman</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2006</year><volume>26</volume><fpage>106</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000191655.87296.ab</pub-id><pub-id pub-id-type="pmid">16239595</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brattbakk</surname><given-names>HR</given-names></name><name><surname>Arbo</surname><given-names>I</given-names></name><name><surname>Aagaard</surname><given-names>S</given-names></name><name><surname>Lindseth</surname><given-names>I</given-names></name><name><surname>de Soysa</surname><given-names>AK</given-names></name><name><surname>Langaas</surname><given-names>M</given-names></name><etal/></person-group><article-title>Balanced caloric macronutrient composition downregulates immunological gene expression in human blood cells-adipose tissue diverges</article-title><source>OMICS</source><year>2013</year><volume>17</volume><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1089/omi.2010.0124</pub-id><pub-id pub-id-type="pmid">21679058</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Christian</surname><given-names>JL</given-names></name><name><surname>Greger</surname><given-names>JL</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Christian</surname><given-names>JL</given-names></name><name><surname>Greger</surname><given-names>JL</given-names></name></person-group><article-title>Energy sources and uses</article-title><source>Nutrition for living</source><year>1994</year><publisher-loc>Redwood City</publisher-loc><publisher-name>Benjamin/Cummings Publishing Co.</publisher-name><fpage>242</fpage><lpage>66</lpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Butte</surname><given-names>NF</given-names></name><name><surname>Caballero</surname><given-names>B</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Shils</surname><given-names>ME</given-names></name><name><surname>Shike</surname><given-names>M</given-names></name><name><surname>Ross</surname><given-names>AC</given-names></name><name><surname>Caballero</surname><given-names>B</given-names></name><name><surname>Cousins</surname><given-names>RJ</given-names></name></person-group><article-title>Energy needs: assessment and requirements</article-title><source>Modern nutrition in health and disease</source><year>2006</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><fpage>136</fpage><lpage>48</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JP</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><name><surname>Naylor</surname><given-names>BA</given-names></name><name><surname>Treacher</surname><given-names>DF</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name></person-group><article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title><source>Diabetologia</source><year>1985</year><volume>28</volume><fpage>412</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/BF00280883</pub-id><pub-id pub-id-type="pmid">3899825</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilensky</surname><given-names>RL</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Mohler</surname><given-names>ER</given-names><suffix>3rd</suffix></name><name><surname>Hamamdzic</surname><given-names>D</given-names></name><name><surname>Burgert</surname><given-names>ME</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development</article-title><source>Nat Med</source><year>2008</year><volume>14</volume><fpage>1059</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/nm.1870</pub-id><pub-id pub-id-type="pmid">18806801</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crujeiras</surname><given-names>AB</given-names></name><name><surname>Parra</surname><given-names>D</given-names></name><name><surname>Milagro</surname><given-names>FI</given-names></name><name><surname>Goyenechea</surname><given-names>E</given-names></name><name><surname>Larrarte</surname><given-names>E</given-names></name><name><surname>Margareto</surname><given-names>J</given-names></name><etal/></person-group><article-title>Differential expression of oxidative stress and inflammation related genes in peripheral blood mononuclear cells in response to a low-calorie diet: a nutrigenomics study</article-title><source>OMICS</source><year>2008</year><volume>12</volume><fpage>251</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1089/omi.2008.0001</pub-id><pub-id pub-id-type="pmid">18687040</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kussmann</surname><given-names>M</given-names></name><name><surname>Raymond</surname><given-names>F</given-names></name><name><surname>Affolter</surname><given-names>M</given-names></name></person-group><article-title>OMICS-driven biomarker discovery in nutrition and health</article-title><source>J Biotechnol</source><year>2006</year><volume>124</volume><fpage>758</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2006.02.014</pub-id><pub-id pub-id-type="pmid">16600411</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WY</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zha</surname><given-names>RP</given-names></name><name><surname>Wang</surname><given-names>YP</given-names></name></person-group><article-title>OxLDL stimulated lipoprotein-associated phopholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways</article-title><source>Cardiovasc Res</source><year>2010</year><volume>85</volume><fpage>845</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvp367</pub-id><pub-id pub-id-type="pmid">19910444</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fratta Pasini</surname><given-names>A</given-names></name><name><surname>Stranieri</surname><given-names>C</given-names></name><name><surname>Pasini</surname><given-names>A</given-names></name><name><surname>Vallerio</surname><given-names>P</given-names></name><name><surname>Mozzini</surname><given-names>C</given-names></name><name><surname>Solani</surname><given-names>E</given-names></name><etal/></person-group><article-title>Lysophosphatidylcholine and carotid intima-media thickness in young smokers: a role for oxidized LDL-induced expression of PBMC lipoprotein-associated phospholiase A2?</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0083092</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumono</surname><given-names>T</given-names></name><name><surname>Konayashi</surname><given-names>T</given-names></name><name><surname>Kamata</surname><given-names>K</given-names></name></person-group><article-title>Role of lysophosphatidyl-choline (LPC) in atherosclerosis</article-title><source>Curr Med Chem</source><year>2007</year><volume>14</volume><fpage>3209</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.2174/092986707782793899</pub-id><pub-id pub-id-type="pmid">18220755</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeill</surname><given-names>AM</given-names></name><name><surname>Rosamond</surname><given-names>WD</given-names></name><name><surname>Girman</surname><given-names>CJ</given-names></name><name><surname>Golden</surname><given-names>SH</given-names></name><name><surname>Schmidt</surname><given-names>MI</given-names></name><name><surname>East</surname><given-names>HE</given-names></name><etal/></person-group><article-title>The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>385</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.2337/diacare.28.2.385</pub-id><pub-id pub-id-type="pmid">15677797</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paik</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>OY</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Jeong</surname><given-names>TS</given-names></name><name><surname>Sweeney</surname><given-names>G</given-names></name><etal/></person-group><article-title>Circulating and PBMC Lp-PLA2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status)</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0029675</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Osman</surname><given-names>H</given-names></name><name><surname>Mohler</surname><given-names>ER</given-names><suffix>3rd</suffix></name><name><surname>Macphee</surname><given-names>C</given-names></name><etal/></person-group><article-title>Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses</article-title><source>Atherosclerosis</source><year>2007</year><volume>191</volume><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2006.05.001</pub-id><pub-id pub-id-type="pmid">16765356</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Keyzer</surname><given-names>D</given-names></name><name><surname>Karabina</surname><given-names>SA</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Geeraert</surname><given-names>B</given-names></name><name><surname>Stengel</surname><given-names>D</given-names></name><name><surname>Marsillach</surname><given-names>J</given-names></name><etal/></person-group><article-title>Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs</article-title><source>Arterioscler Thrombo Vasc Biol</source><year>2009</year><volume>29</volume><fpage>2041</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.109.196592</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name></person-group><article-title>Nutritionally mediated oxidative stress and inflammation</article-title><source>Oxid Med Cell Longev</source><year>2013</year><volume>2013</volume><fpage>610950</fpage><pub-id pub-id-type="doi">10.1155/2013/610950</pub-id><pub-id pub-id-type="pmid">23844276</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belobrajdic</surname><given-names>DP</given-names></name><name><surname>Bird</surname><given-names>AR</given-names></name></person-group><article-title>The potential role of phytochemicals in wholegrain cereals for the prevention of type-2 diabetes</article-title><source>Nutr J</source><year>2013</year><volume>12</volume><fpage>62</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1186/1475-2891-12-62</pub-id><pub-id pub-id-type="pmid">23679924</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>IM</given-names></name><name><surname>Cole</surname><given-names>SR</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Fruit and vegetable intake and risk of cardiovascular disease: the Women&#x02019;s Health Study</article-title><source>Am J Clin Nutr</source><year>2000</year><volume>72</volume><fpage>922</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11010932</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>DR</given-names><suffix>Jr</suffix></name><name><surname>Andersen</surname><given-names>LF</given-names></name><name><surname>Blomhoff</surname><given-names>R</given-names></name></person-group><article-title>Whole-grain consumption is associated with a reduced risk of noncardiovascular, noncancer death attributed to inflammatory disease in the lowa Women&#x02019;s Health Study</article-title><source>Am J Clin Nutr</source><year>2007</year><volume>85</volume><fpage>1606</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">17556700</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crujeiras</surname><given-names>AB</given-names></name><name><surname>Parra</surname><given-names>D</given-names></name><name><surname>Abete</surname><given-names>I</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>JA</given-names></name></person-group><article-title>A hypocaloric diet enriched in legumes specifically mitigates lipid peroxidation in obese subjects</article-title><source>Free Radic Res</source><year>2007</year><volume>41</volume><fpage>498</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1080/10715760601131935</pub-id><pub-id pub-id-type="pmid">17454132</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>HK</given-names></name><name><surname>Chae</surname><given-names>JS</given-names></name><name><surname>Hyun</surname><given-names>YJ</given-names></name><name><surname>Paik</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Jang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Influence of adiponectin gene polymorphisms on adiponectin level and insulin resistance index in response to dietary intervention in overweight-obese patients with impaired fasting glucose or newly diagnosed type 2 diabetes</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>552</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2337/dc08-1605</pub-id><pub-id pub-id-type="pmid">19131459</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>CY</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Paik</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>OY</given-names></name><name><surname>Paik</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes</article-title><source>Clin Endocrinol</source><year>2012</year><volume>76</volume><fpage>674</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2265.2011.04244.x</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skoog</surname><given-names>T</given-names></name><name><surname>Dichtl</surname><given-names>W</given-names></name><name><surname>Boquist</surname><given-names>S</given-names></name><name><surname>Skoglund-Andersson</surname><given-names>C</given-names></name><name><surname>Karpe</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Plasma tumour necrosis factor-&#x003b1; and early carotid atherosclerosis in healthy middle-aged men</article-title><source>Eur Heart J</source><year>2002</year><volume>23</volume><fpage>376</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1053/euhj.2001.2805</pub-id><pub-id pub-id-type="pmid">11846495</pub-id></element-citation></ref></ref-list></back></article>